Profiling the microbiome in pancreatic ductal adenocarcinoma
Advisor Information
Dr. Cooper
Location
MBSC Ballroom - Poster #501 - U
Presentation Type
Poster
Start Date
4-3-2022 9:00 AM
End Date
4-3-2022 10:15 AM
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth-most diagnosed cancer in the world. The gut microbiome is key to understanding PDAC. The microbiome has shown to undergo changes during the course of treatment, often interfering with the efficacy of various treatments. These changes have led researchers to investigate how the microbiome may be targeted as a treatment approach. This project explores currently available datasets for and reviews the current research investigating whether specific microbiome profiles are associated with particular cancer phenotypes. Results of this project will inform future research on drug-related temporal changes of the microbiome, which can be leveraged to predict treatment response and refine treatment approaches in treatment-resistant sub-types..
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Scheduling Link
1
Profiling the microbiome in pancreatic ductal adenocarcinoma
MBSC Ballroom - Poster #501 - U
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth-most diagnosed cancer in the world. The gut microbiome is key to understanding PDAC. The microbiome has shown to undergo changes during the course of treatment, often interfering with the efficacy of various treatments. These changes have led researchers to investigate how the microbiome may be targeted as a treatment approach. This project explores currently available datasets for and reviews the current research investigating whether specific microbiome profiles are associated with particular cancer phenotypes. Results of this project will inform future research on drug-related temporal changes of the microbiome, which can be leveraged to predict treatment response and refine treatment approaches in treatment-resistant sub-types..